Chemify and Sanacor Join Forces to Tackle Diabetic Cardiovascular Disease
Why is the discovery of new therapies for diabetic cardiovascular disease so critical? Chemify, a deep-tech pioneer in Chemputation, and Sanacor Inc., a biotechnology company focused on mitochondrial dysfunction, have announced a strategic collaboration to develop novel small-molecule inhibitors. This partnership aims to address the significant unmet medical needs in cardiometabolic diseases, with an initial focus on diabetic cardiovascular disease.
Chemify’s Chemputation technology, which combines machine learning (ML)-based molecular discovery and automated, robotic synthesis, will work in tandem with Sanacor’s deep biological expertise. “Our platform allows us to rapidly design, make, and refine novel, highly efficacious small molecules in a tightly integrated workflow, giving teams the ability to move from biological insight to optimized compounds with speed and confidence,” said Lee Cronin, CEO and Founder of Chemify.
Key Insights at a Glance
- Chemputation Technology: Chemify’s platform integrates ML-based design, a universal programming language for chemistry, advanced software, and robotics.
- Mitochondrial Dysfunction: Sanacor’s research highlights the central role of mitochondrial dynamics in diabetic cardiovascular disease.
- First-in-Class Therapies: The collaboration aims to develop first-in-class therapeutic candidates addressing major unmet medical needs.
- Rapid Iteration: The closed-loop workflow accelerates the discovery process, enhancing design confidence and speed.
Why Mitochondrial Dysfunction is a Critical Target in Diabetic Cardiovascular Disease
Mitochondrial dysfunction is a root cause of vascular disease in diabetes, leading to endothelial dysfunction and subsequent complications. Despite the significant impact of diabetic cardiovascular disease, there are currently no therapies that directly target the underlying vascular dysfunction. This gap in treatment options highlights the urgent need for innovative solutions. The collaboration between Chemify and Sanacor is poised to address this critical issue, potentially transforming the landscape of cardiometabolic disease management.
Accelerating Discovery with a Fresh Approach
Just as a master chef combines ingredients to create a unique dish, Chemify and Sanacor are blending their expertise to develop groundbreaking therapies. By leveraging Chemify’s Chemputation technology, the partnership can rapidly design and synthesize novel small molecules, while Sanacor’s deep biological insights ensure these compounds are precisely targeted to address mitochondrial dysfunction. This integrated approach not only accelerates the discovery process but also enhances the likelihood of developing effective treatments for diabetic cardiovascular disease.
Chemify’s Chemputation Technology: A Game-Changer in Drug Discovery
Chemify’s Chemputation technology is revolutionizing the way small molecules are designed and synthesized. Chemify’s platform integrates ML-based design, a universal programming language for chemistry, advanced software, and robotics, enabling seamless transition from concept to compound. This technology allows for the rapid generation of optimized compounds with strong potency and drug-like properties. “Chemify’s Chemputation technology provides an opportunity to translate that science into drug candidates with real clinical potential, allowing us to make an impact on the millions of patients suffering from cardiometabolic diseases,” said Dr. Michael Widlansky, CEO and Co-founder of Sanacor.
Future Outlook
The collaboration between Chemify and Sanacor is just the beginning of a broader effort to address mitochondrial dysfunction across various diseases. As research continues to uncover the role of mitochondrial dynamics in conditions such as diabetic kidney and retinal disease, neurodegeneration, oncology, and rare mitochondrial disorders, the potential applications of this technology are vast. The future of drug discovery is evolving, and this partnership is setting a new standard for how biotechnology and deep-tech can work together to solve complex medical challenges.
Conclusion
The partnership between Chemify and Sanacor marks a significant step forward in the fight against diabetic cardiovascular disease. For the biotechnology and pharmaceutical industries, this collaboration underscores the importance of integrating advanced technologies with deep biological expertise to address unmet medical needs. How is your organization preparing to leverage such innovative approaches in your research and development efforts? Join the conversation in the comments below.
About Chemify
Chemify is reimagining the discovery and synthesis of novel molecules for medicines and advanced materials by turning digital code into physical compounds through Chemputation—its fusion of robotics and AI. Headquartered in Glasgow, Scotland, the company was founded by Lee Cronin to digitalize chemistry at global scale for the benefit of humanity.
About Sanacor
Sanacor is a biotechnology company developing therapies that target mitochondrial dysfunction in cardiometabolic diseases, with an initial focus on reversing diabetic cardiovascular disease. The company’s scientific foundation is supported by nearly two decades of research and has been funded by the National Institutes of Health (NIH), the American Heart Association (AHA), and the American Diabetes Association (ADA).
Cardiovascular disease remains the leading cause of mortality among individuals with diabetes, and there are currently no approved disease-modifying therapies that address its underlying pathophysiology. Leveraging its mitochondrial biology platform, Sanacor is also investigating applications across additional diabetic complications (including kidney and retinal disease) as well as neurodegeneration, oncology, and rare mitochondrial disorders.
Source link: https://www.businesswire.com/
